Berberis

Berberis (Unspecified): A Comprehensive Reference

1. Identity and Botanical Description

Taxonomy and Common Names

The genus Berberis, with more than 500 species, belongs to the family Berberidaceae. When dietary supplements and traditional medicine preparations are labeled simply as "Berberis (unspecified)," they may derive from any of several widely used species. The most pharmacologically studied include Berberis vulgaris L. (common or European barberry), Berberis aristata DC. (Indian barberry, tree turmeric, Daru Haldi, Daruharidra), Berberis aquifolium (Oregon grape), and Berberis asiatica. Specifically, Berberis vulgaris is an evergreen shrub that possesses yellow, spiny, angled or sulcated bark, oblong, obovate, or elliptic leaves, yellow flowers, and red, oblong fruits. It grows in Asia and Europe and is a well-known herb in Iran.

Berberis aristata, belonging to the family Berberidaceae, is considered a vital herb in many traditional medicinal systems, and is also known by other names including Indian barberry, Tree Turmeric, Daru Haldi, Chitra, and Daruharida. Berberine — the principal bioactive compound of the genus — is a compound found in plants such as European barberry, goldenseal, goldthread, Oregon grape, phellodendron, and tree turmeric.

Plant Parts Used

While only the berries of Berberidaceae plants are consumed as food, it is the roots, rhizomes, and bark of Berberis plants that are used medicinally; these berberine-rich portions have been applied for centuries in traditional Chinese, Ayurvedic, and Native American medicines. Within the genus Berberis, the distribution of berberine and other alkaloids is mostly in the root, followed by the stem bark and the stem itself; its presence in trace amounts has also been reported from leaves and berries.

Common Preparations and Forms

Preparations of Berberis species include dried root and bark powders, decoctions, tinctures, standardized aqueous or hydroalcoholic extracts, and isolated berberine hydrochloride (berberine HCl) as a purified supplement. The hydrochloride salt of berberine is listed as an oral antibacterial agent in the Pharmacopoeia of the People's Republic of China and is a common over-the-counter medication, colloquially known as Huangliansu (黄连素). In Western supplement markets, preparations commonly appear as standardized-extract capsules or tablets, frequently delivering berberine HCl. Advanced analytical studies confirm that different extraction techniques — including Soxhlet, ultrasound-assisted, microwave, maceration, and supercritical CO₂ extraction — yield distinct chemical profiles.

2. Traditional and Historical Use

Antiquity and Cross-Cultural Reach

The oldest documented use of barberry fruit — specifically for purifying blood — was inscribed on clay tablets in the library of Assyrian (present-day Iraq) emperor Asurbanipal during 650 BC. In Asia, the extensive use of the stem, stem bark, roots, and root bark of plants rich in berberine, particularly Berberis species, has more than 3,000 years of history, and these plants have been used as raw material or as an important ingredient in Ayurvedic and traditional Chinese medicine.

Ayurvedic Medicine

In Ayurveda, Berberis species have been traditionally used for the treatment of a wide range of infections of the ear, eye, and mouth, for quick healing of wounds, curing hemorrhoids, indigestion and dysentery, and for treatment of uterine and vaginal disorders. It has also been used to reduce obesity, and as an antidote for the treatment of scorpion sting or snakebite. B. aristata is described in Ayurvedic texts as having properties classified as Arshoghna (anti-haemorrhoidal), Kandughna (anti-pruritic), Lekhaniya (reducing toxicity and unnecessary fats), Rasayana (rejuvenating), Ropana (a wound healer), Stanyasodhana (lactose purifier), and Svedala (promotes sweating).

Among other traditionally cited indications for B. aristata, frequently mentioned are liver, gallbladder, and pancreatic disorders, difficult-to-heal wounds and skin inflammation or infection, hemorrhoids, malaria, leprosy, dysentery, urinary tract ailments, plague infection, and menopause.

Traditional Chinese Medicine

Berberis has been used in traditional Chinese medicine for centuries in the treatment of liver disorders, diarrhea, and gastroenteritis. In China, berberine is used as an over-the-counter drug to treat infectious diarrhea. Singapore has withdrawn the use of two commonly used berberine-containing Chinese herbs, Rhizoma coptidis and Cortex phellodendri, for several decades due to implication of berberine in exacerbating jaundice and kernicterus in neonates.

Iranian and Yunani Medicine

In Iranian traditional medicine, Berberis is used to cure jaundice, enlarged liver, enlarged spleen, eye sores, toothache, asthma, and skin pigmentation, and to dry unhealthy ulcers, as well as to eliminate swelling and inflammation both orally and topically. In Yunani medicine, Berberis asiatica has multiple uses, including the treatment of asthma, eye sores, jaundice, skin pigmentation, and toothache, as well as favoring the elimination of inflammation and swelling, and for drying ulcers.

Cross-Traditional Antimicrobial Use

Berberis-containing extracts and decoctions are traditionally used for their activities against a variety of microorganisms — including bacteria, viruses, fungi, protozoa, and helminths — in Ayurvedic, Chinese, and Middle-Eastern folk medicines. Berberine-containing plants were commonly used for the treatment of diarrhea and microbial infection, properties that may be a direct consequence of berberine's strong antimicrobial effects.

3. Key Phytochemical Constituents

Primary Alkaloids

Phytochemical investigations of various species of Berberis have led to the isolation of alkaloids, tannins, phenolic compounds, sterols, and triterpenes. The main isolated compounds from B. vulgaris are tannins, phenolic compounds, triterpenes (lupeol, oleanolic acid), sterols (stigmasterol, stigmasterol glucoside), and alkaloids including berberamine, palmatine, berberine, oxyberberine, columbamine, isocorydine, lambertine, and magnoflorine. Additionally, bisbenzylisoquinolines (oxycanthine), N-(p-trans-coumaroyl) tyramine, cannabisin G, and (±)-lyoniresinol have been isolated from this plant.

The most common alkaloids reported from B. aristata are berberine, berbamine, oxyberberine, palmatine, karachine, aromoline, taxilamine, and oxyacanthine, with several of these concentrated particularly in the roots. Phenolics including rutin, quercetin, meratin, chlorogenic acid, and caffeic acid have also been reported in the flowers of B. aristata.

Berberine: The Principal Bioactive

Berberine (BBR), a quaternary ammonium salt belonging to a group of benzylisoquinoline alkaloids, is the most active compound reported from Berberis species and is considered to be highly effective against diabetes and other metabolic diseases. BBR is also distributed in various plant species of other genera such as Coptis, Hydrastis, Mahonia, Tinospora, Xanthorhiza, and many others. In the genus Berberis, the distribution of BBR and other alkaloids is mostly in its root.

Research on Berberis darwinii showed that roots had the highest concentrations of both berberine and palmatine, followed by stems, while leaves and seeds had lower levels, and the pulp from fruits had no detectable alkaloids.

Secondary Alkaloids: Palmatine and Berbamine

Palmatine (PLT) is a natural isoquinoline alkaloid that belongs to the class of protoberberines and exhibits a wide spectrum of pharmacological and biological properties, including anti-cancer activity. Many other alkaloids belonging to isoquinolines have been identified in barberry shrubs, including berberine, magnoflorine, jatrorrhizine, oblongine, oxyacanthine, berbamine, penduline, and others. The phytochemical analysis of barberry root and stem also revealed the presence of bisbenzylisoquinoline alkaloids — berbamine, tetrandrine, and chondocurine — with anti-inflammatory and immunosuppressive properties.

Non-Alkaloid Constituents

In addition to alkaloids, the roots of B. vulgaris contain organic acids such as chelidonic acid, citric acid, malic acid, resin, tannin, pectinic, and mucilagic substances; the fruit is sour and contains sugars such as dextrose and fructose, malic acid, pectin, gum, tartaric, and citric acids.

4. Established Mechanisms of Action

AMPK Activation and Glucose Metabolism

The antidiabetic activity of berberine has been attributed to its pleiotropic mechanisms, involving activation of AMP-activated protein kinase (AMPK), inhibition of mitogen-activated protein kinases (MAPK), inhibition of the PI3K/Akt signaling pathway, inhibition of aldose reductase, inhibition of inflammation, inhibition of oxidative stress, and modulation of lipid metabolism. The activation of AMPK is frequently mediated by pathways involving LKB1 and CAMKKβ; berberine's activation of AMPK positively impacts glucose uptake, insulin sensitivity, lipid metabolism, oxidative stress, and inflammatory responses.

However, the AMPK pathway does not fully explain berberine's glucose-lowering effects. Research has shown that the activity of respiratory chain complex I was almost fully blocked in C2C12 myotubes by berberine; metformin showed similar effects, suggesting that both compounds promote glucose metabolism by stimulating glycolysis, which probably results from inhibition of mitochondrial respiratory chain complex I, independent of AMPK activation.

Additionally, berberine has been shown to optimize blood glucose levels by stimulating β cells of the pancreas for insulin secretion, and it is also capable of acting as an α-glycosidase inhibitor, especially in the intestine, thereby delaying the absorption of glucose.

Lipid Metabolism: PCSK9 and LDL Receptor Upregulation

Berberine treatment boosts hepatic expression of LDL receptors (LDLRs) while decreasing the expression and secretion of the LDLR modulator PCSK9. Sterol regulatory element-binding protein (SREBP) and hepatocyte nuclear factor 1α (HNF1α) control PCSK9 protein synthesis at the transcriptional level; through ubiquitin-proteasome degradation, BBR inhibits SREBP2 and HNF1α expression, resulting in blood PCSK9 levels being lowered via decreased transcription of its mRNA and resulting in increased LDLR mRNA expression.

Anti-Inflammatory and Antioxidant Mechanisms

Both B. vulgaris and berberine can inhibit the production of pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6, and IL-17, and enhance the expression of anti-inflammatory cytokines such as IL-10 and transforming growth factor; they can also scavenge free radicals, increase antioxidant enzymes — including superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) — and reduce lipid peroxidation and DNA damage.

Gut Microbiome Modulation

Berberine promotes the growth of beneficial bacteria such as Bacteroides, Bifidobacterium, and Lactobacillus while reducing harmful bacteria such as Escherichia coli. Furthermore, gut bacteria convert berberine into bioactive metabolites, contributing to enhanced intraluminal activity despite its low systemic bioavailability.

5. Scientific Evidence by Area of Use

5.1 Glucose Metabolism and Type 2 Diabetes

Evidence strength: Moderate-to-good for short-term glycemic outcomes in clinical trials; evidence on long-term outcomes and hard endpoints remains limited.

The therapeutic efficacy of berberine against type 2 diabetes mellitus (T2DM) was first reported in 1986 in mice and in 1988 in a diabetic patient. In newly diagnosed type 2 diabetic patients, hemoglobin A1c was decreased from approximately 9.5% to approximately 7.5% after berberine treatment for 3 months; the study indicated that berberine was a potent oral hypoglycemic agent with beneficial effects on lipid metabolism.

Based on success demonstrated at the preclinical stage, several clinical trials have been conducted to evaluate efficacy and safety of berberine and its subsequent use as a medicine to treat diabetes in humans. Clinical trials reported significant reductions in fasting blood glucose (FBG), HbA1c, and lipid levels, with minimal side effects, at standard doses. BBR could ameliorate insulin resistance in patients with diabetes and lower blood sugar and HbA1c in patients with T2DM.

There is some evidence that berberine may have a modest effect on lowering blood glucose levels in people with type 2 diabetes and may reduce cholesterol levels. The NIH's National Center for Complementary and Integrative Health (NCCIH) characterizes the glycemic evidence as preliminary, noting ongoing limitations in study quality.

5.2 Dyslipidemia and Cardiovascular Risk Factors

Evidence strength: Moderate clinical evidence from multiple RCTs and meta-analyses; methodological limitations acknowledged.

A systematic review and meta-analysis of randomized clinical trials showed that berberine significantly reduced total cholesterol (MD = −0.47 mmol/L, 95% CI [−0.64, −0.31], p < 0.00001), LDL-C (MD = −0.38 mmol/L, 95% CI [−0.53, −0.22], p < 0.00001), and triglycerides (MD = −0.28 mmol/L, 95% CI [−0.46, −0.10], p = 0.002); berberine also increased HDL-C when used alone (MD = 0.08 mmol/L, 95% CI [0.03, 0.12], p = 0.001). No significant differences were found between groups in terms of incidence of adverse events, and no severe adverse effects were reported in either group.

One mechanistic randomized controlled trial administered purified berberine tablets at 500 mg orally twice daily, which had been shown to be safe and effective in lipid-lowering in previous trials, for 12 weeks. That study showed that berberine lowers total cholesterol and possibly LDL-C, with good safety.

Berberine has been mentioned by the International Lipid Expert Panel and the 2019 European Atherosclerosis Society/European Society of Cardiology Guidelines for the treatment of hyperlipidemia in statin-intolerant patients; however, these guidelines have not provided explicit recommendations about the use of berberine because of the lack of high-quality evidence. Systematic reviews and meta-analyses of clinical trials have shown a lipid-lowering effect of berberine in people with hyperlipidemia with or without coronary heart disease or diabetes, as well as potential benefits on blood pressure and adiposity, with no serious adverse events; however, these trials vary in quality and design, making meta-analyses difficult to interpret, and publication bias is also possible.

Berberine may have additional beneficial effects on high blood pressure when used in combination with the medication amlodipine.

5.3 Obesity and Body Weight

Evidence strength: Preliminary — limited number of clinical trials specifically targeting body weight; evidence is insufficient to draw firm conclusions (NCCIH).

Obesity is closely related to an increased risk of T2DM; BBR could successfully decrease body weight, body mass index, and waist circumference in obese patients with T2DM. While some preliminary studies have suggested that berberine may play a role in losing weight, there haven't been many clinical trials, so there isn't enough rigorous scientific evidence to determine whether it is effective.

5.4 Non-Alcoholic Fatty Liver Disease (NAFLD)

Evidence strength: Preliminary; limited clinical data, mostly short-term studies.

BBR can improve hepatic fat content, apolipoprotein B (Apo B), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) in patients with NAFLD. These findings come from a limited number of clinical studies, and further well-controlled trials are required before firm conclusions can be drawn.

5.5 Anti-Inflammatory and Immunomodulatory Effects

Evidence strength: Mechanistically well-characterized in preclinical models; clinical evidence from human trials is more limited and largely in the context of comorbid metabolic disease.

Both B. vulgaris and berberine have shown anti-inflammatory, antioxidant, and immunomodulatory effects in different experimental models and clinical trials. Berberine represents a promising adjuvant therapy for inflammatory diseases, particularly intestinal disorders, due to its multifaceted actions of inhibiting proinflammatory cytokines and pathways during IBS, IBD, and UC, and its modulation of gut microbiota and/or enhancement of the integrity of the intestinal epithelial barrier.

5.6 Antimicrobial Activity

Evidence strength: Well-established in vitro and some preclinical data; human clinical evidence for most infectious indications remains limited.

Berberine extracts and decoctions are traditionally used for their activities against a variety of microorganisms — including bacteria, viruses, fungi, protozoa, and helminths — in Ayurvedic, Chinese, and Middle-Eastern folk medicines. Predominant clinical uses of berberine include treatment of bacterial diarrhea, intestinal parasite infections, and ocular trachoma infections.

5.7 Oncology (Anticancer Research)

Evidence strength: Preclinical only — in vitro and animal model data are extensive; no established clinical evidence as an anticancer therapy in humans.

Berberine is currently receiving considerable interest due to its anticancer activity based on many biochemical pathways, especially its proapoptotic and anti-inflammatory activity; it not only possesses documented proapoptotic activity but also seems to be a very important and promising compound in combined cancer treatment. Berberine exhibits low toxicity towards healthy cells, which makes it safe for clinical use and proves its activity in biochemical disorders. Translation to human cancer outcomes has not been demonstrated in robust clinical trials to date.

5.8 Cardiovascular and Ischemic Heart Disease Risk

Evidence strength: Preliminary; association data and small trial evidence; large RCTs confirming hard endpoints are lacking.

Using Mendelian randomization in UK Biobank data, a berberine-associated signature was related to lower ischemic heart disease (IHD) and diabetes risks (OR for IHD 0.85, 95% CI 0.79–0.91; diabetes 0.88, 95% CI 0.80–0.96). The study's authors concluded that beneficial associations of berberine with IHD and diabetes require confirmation in large clinical trials.

5.9 Neurodegenerative and Neurological Associations

Evidence strength: Largely in vitro and animal model data; insufficient human evidence at this time.

According to several studies, B. vulgaris and berberine exhibited anticonvulsant, antidepressant, and anti-Alzheimer effects in both in vitro and in vivo experiments. In extracts from various Berberis species, a high content of berberine and palmatine was determined, and alkaloid standards and most of the investigated plant extracts exhibit significant anti-cholinesterase activity — a mechanism relevant to Alzheimer's disease research. Clinical human data are not yet available to support therapeutic claims in this domain.

6. Body Systems and Health Areas Associated with Berberis

• Metabolic/Endocrine: Blood glucose regulation, insulin sensitivity, lipid profile, weight management, NAFLD
• Cardiovascular: Cholesterol reduction, blood pressure, anti-arrhythmic effects (preclinical), atherosclerosis risk
• Gastrointestinal: Antimicrobial diarrhea treatment, gut microbiome modulation, IBD/IBS, intestinal barrier integrity
• Immune/Inflammatory: Cytokine modulation, immunomodulation, anti-inflammatory activity
• Hepatic: Liver fat, liver enzyme normalization, hepatoprotective effects (preclinical and limited clinical)
• Antimicrobial: Activity against bacteria, viruses, fungi, protozoa, and helminths
• Neurological: Anti-cholinesterase activity, neuroprotection (preclinical)
• Oncological: Proapoptotic, anti-proliferative (in vitro and animal models only)

B. vulgaris and berberine have been reported to exert beneficial effects in several inflammatory, oxidative, and immune-related diseases, including diabetes, obesity, cardiovascular diseases, neurodegenerative diseases, autoimmune diseases, allergic diseases, and infections.

7. Dosage Forms and Clinically Studied Dosages

Dosage Forms

Berberis preparations are available as capsules or tablets (often containing berberine HCl), dried root powder, decoctions, and tinctures. In China, the hydrochloride salt of berberine is available in pill form, with an approved dosage of 0.1 g (100 mg) taken 1–3 times per day for gastrointestinal infections. In the US, berberine is available as a dietary supplement at doses of 100 to 200 mg/day, and has been approved by the Chinese Food and Drug Administration (CFDA) for diarrhea at a dose of 300 mg three times daily.

Dosages Reported in Clinical Studies

Clinical studies have evaluated berberine HCl at dosages ranging from 500 mg to 1500 mg per day for as long as six months in adults. The berberine dosage used in nearly every positive clinical trial is 500 mg taken two to three times daily with meals, totaling 1,000–1,500 mg/day. In clinical studies for diabetes, cardiovascular disease, and hyperlipidemia, oral doses as high as 1500 mg berberine per day for three months were administered; no severe adverse effects and no significant changes in plasma kidney and liver parameters were observed, though mild to moderate constipation was seen in 3–8% of subjects.

A mechanistic randomized controlled trial administered purified berberine tablets at 500 mg orally twice daily (total 1000 mg/day) for 12 weeks.

Bioavailability and Pharmacokinetics

In rats, absolute bioavailability is reported below 1%; in a pharmacokinetic study involving 20 human participants who received a single 400 mg oral dose of BBR, the maximum plasma concentration (Cmax) reached approximately 0.4 ng/mL. The lower in vivo bioavailability of berberine is closely related to extensive intestinal first-pass elimination, in which the drug is filtered out of circulation by the liver; after oral administration to rats, approximately half of berberine passed intact through the gastrointestinal tract and another half was disposed of by the small intestine, resulting in an extremely low absolute oral bioavailability of approximately 0.36%.

It has been shown that oral bioavailability of berberine is below 1%; factors such as the first-pass effect in the intestine, interaction with P-glycoprotein (P-gp) pumps, and high extraction and distribution in the liver are involved in its poor oral bioavailability. Despite this, clinical efficacy has been observed, likely due to berberine's high local concentrations in the gut and metabolite activity.

8. Safety Considerations and Drug Interactions

General Tolerability

In general, when taken orally, berberine is well tolerated; however, it is not without its risks and side effects. The most common adverse effects include abdominal pain, constipation, diarrhea, nausea, and vomiting.

Pregnancy and Breastfeeding

People who are pregnant or breastfeeding should not use berberine, and it should not be given to infants; berberine can cause or worsen jaundice in newborn infants and could lead to a life-threatening problem called kernicterus. One study suggests that berberine might cause uterine contractions. Due to the uterine-stimulatory effect of berberine-containing plants, use in pregnancy is cautioned.

Neonatal and Infant Risk

Exposure to berberine has been linked to a harmful buildup of bilirubin in infants, which can cause brain damage; therefore, berberine is likely to be unsafe for infants and may also be unsafe for use during pregnancy or while breastfeeding because of possible effects on the fetus or infant.

Cyclosporine and Organ Transplant Patients

Berberine has been shown to interact with cyclosporine, a drug used to prevent rejection of transplanted organs. Cyclosporin A bioavailability increased in renal transplant patients after berberine administration, which may be due to a decrease in or inhibition of CYP3A4 in the liver and/or intestine.

Cytochrome P450 (CYP) Enzyme Inhibition

After two weeks of berberine (300 mg, three times daily) administration to healthy male volunteers, decreases in CYP2D6 activity (dextromethorphan/dextrorphan ratio increased ninefold, p < 0.01), CYP2C9 activity (losartan/E-3174 ratio doubled, p < 0.01), and CYP3A4 activity (midazolam Cmax increased 38%, AUC0–∞ increased 40%, p < 0.01) were observed. This inhibition means berberine may substantially increase plasma levels of co-administered drugs metabolized by these enzymes.

Hypoglycemia Risk with Antidiabetic Medications

Stacking berberine on top of metformin, sulfonylureas, insulin, or GLP-1 agonists can produce hypoglycemia, as berberine's glucose-lowering effects are additive with these agents.

Hepatotoxicity

No evidence of liver damage has been found in any published clinical trial at standard doses, and the NIH's LiverTox database classifies berberine as an unlikely cause of clinically apparent liver injury.

Evidence Gaps and Limitations Across the Literature

More studies are needed to elucidate the optimal doses, safety profiles, and potential interactions of B. vulgaris and berberine with other drugs or natural compounds. In published meta-analyses, the methodological quality of the majority of trials was generally low in terms of random sequence generation, allocation concealment, blinding, and incomplete outcome data, meaning selection bias, performance bias, detection bias, attrition bias, and confounding bias might exist.

References

• Imenshahidi M, Hosseinzadeh H. Anti-inflammatory, antioxidant, and immunomodulatory effects of Berberis vulgaris and its constituent berberine, experimental and clinical, a review. PubMed, 2024.
• Neag MA et al. Berberine: Botanical Occurrence, Traditional Uses, Extraction Methods, and Relevance in Cardiovascular, Metabolic, Hepatic, and Renal Disorders. Frontiers in Pharmacology / PMC, 2018.
• Imenshahidi M, Hosseinzadeh H. Berberis vulgaris and its constituent berberine as antidotes and protective agents against natural or chemical toxicities. PMC, 2017.
• Akhtar MF et al. Phytopharmacology and Clinical Updates of Berberis Species Against Diabetes and Other Metabolic Diseases. PMC, 2020.
• Rząsa-Duran E et al. Biological Activity of Berberine — A Summary Update. PMC, 2020.
• Farzaei MH et al. Berberis vulgaris: specifications and traditional uses. PMC, 2017.
• Addressing the preventive and therapeutic perspective of berberine against diabetes. PMC / Heliyon, 2023.
• Xu M et al. Berberine Promotes Glucose Consumption Independently of AMP-Activated Protein Kinase Activation. PMC / PLOS ONE, 2014.
• National Center for Complementary and Integrative Health (NCCIH). In the News: Berberine. NIH.
• NCCIH. Berberine and Weight Loss: What You Need To Know. NIH.
• NCCIH. Herb-Drug Interactions: What the Science Says. NIH.
• Liang Y et al. Effect of Berberine on Cardiovascular Disease Risk Factors: A Mechanistic Randomized Controlled Trial. PMC / Nutrients, 2021.
• Lan J et al. Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials. PubMed, 2018.
• Liang Y et al. Berberine signature and cardiometabolic diseases using randomized controlled trial, cohort study, and Mendelian randomization. PMC, 2025.
• Rahimi R et al. Toxicology effects of Berberis vulgaris (barberry) and its active constituent, berberine: a review. PMC, 2017.
• Czernek D et al. Palmatine, a Bioactive Protoberberine Alkaloid Isolated from Berberis cretica, Inhibits the Growth of Human Estrogen Receptor-Positive Breast Cancer Cells. PMC, 2021.
• Comparative study of alkaloid and phenolic compounds in different organs of Berberis integerrima. PMC, 2025.
• Imenshahidi M, Hosseinzadeh H. A quick overview on some aspects of endocrinological and therapeutic effects of Berberis vulgaris L. PMC, 2015.
• Efficacy and underlying mechanisms of berberine against lipid metabolic diseases: a review. PMC, 2023.
• Berberine: Ins and outs of a nature-made PCSK9 inhibitor. PMC, 2022.
• Perspectives on Berberine and the Regulation of Gut Microbiota: As an Anti-Inflammatory Agent. PMC, 2025.
• The mechanism of berberine alleviating metabolic disorder based on gut microbiome. PMC, 2022.
• Guo Y et al. Repeated administration of berberine inhibits cytochromes P450 in humans. PMC, 2016.
• Jiang L et al. Berberine: A Review of its Pharmacokinetics Properties and Therapeutic Potentials in Diverse Vascular Diseases. PMC / Frontiers in Pharmacology, 2021.
• MotherToBaby Fact Sheet: Berberine. NIH NCBI Bookshelf, 2023.
• Berberine and Palmatine Distribution Across Plant Organs in Berberis darwinii. PMC, 2025.
• Zamani M et al. The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis. Frontiers in Nutrition, 2022.
• Berberine in Bowel Health: Anti-Inflammatory and Gut Microbiota Modulatory Effects. PMC, 2025.